Structure Therapeutics is trading 4.2% down at $47.52 as investors react to recent insider selling and engage in profit-taking following a major rally tied to its obesity-drug update. - The company's Chief Scientific Officer, Xichen Lin, recently sold 7,878 American Depositary Shares (ADS) on July 14, 2026, which may be contributing to selling pressure. - Broader market sentiment is also contributing to the decline, with the NASDAQ Composite down approximately 0.77% as biotech and technology names face general selling pressure.